Neuroendocrine tumors are uncommon clinical entities and only a few cases of the co-occurrence of neuroendocrine tumors and retroperitoneal fibrosis have been described in the literature.
Methods and Study Design:
We report the promising results achieved in a case of neuroendocrine tumor complicated by retroperitoneal fibrosis causing right ureteral obstruction treated with long-acting release octreotide and tamoxifen.
Results and Conclusions
The treatment resulted in a complete response without toxicity.
DruceM.R., BharwaniN., AkkerS.A., DrakeW.M., RockallA., GrossmanA.B.Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine (‘carcinoid’) tumours of the small bowel. QJM.2010; 103(3): 177–185.
2.
ModlinI.M., ShapiroM.D., KiddM.Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum Pathol.2004; 35(12): 1440–1451.
3.
KlöppelG., PerrenA., HeitzP.U.The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci.2004; 1014(1): 13–27.
4.
ModlinI.M., KiddM., LatichI., ZikusokaM.N., ShapiroM.D.Current status of gastrointestinal carcinoids. Gastroenterology.2005; 128(6): 1717–1751.
5.
ShenoyS.Gastrointestinal carcinoids and colorectal cancers: is it a paracrine effect?Tumori.2013; 99(4): e141–e143.
DruceM., RockallA., GrossmanA.B.Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol.2009; 5(5): 276–283.
11.
RheeR.Y., GloviczkiP., LuthraH.S., StansonA.W., BowerT.C., CherryK.J.Jr.. Iliocaval complications of retroperitoneal fibrosis. Am J Surg.1994; 168(2): 179–183.
12.
AnwarN., TaylorP.M., CarrolR.N.P., RamsdenR.T., MerchantM., GokalR.An unusual case of retroperitoneal fibrosis. Am J Kidney Dis.1993; 22(1): 57–59.
13.
KottraJ.J., DunnickN.R.Retroperitoneal fibrosis. Radiol Clin North Am.1996; 34(6): 1259–1275.
14.
DevS., al-DujailyS., SubbuswamyS.G.A case of ureteric obstruction, retroperitoneal fibrosis, and carcinoid tumour. Postgrad Med J.1999; 75(879): 38–40.
15.
FrankartL., LorgeF., DonckierJ.Tamoxifen for retroperitoneal fibrosis. Postgrad Med J.1997; 73(864): 653–654.
16.
Gwynne-JonesD.P., TheisJ.C., JefferyA.K., HungN.A.Long-term follow-up of a recurrent multifocal desmoid tumour treated with tamoxifen: a case report. J Orthop Surg (Hong Kong).2005; 13(2): 174–177.
17.
ClarkC.P., VanderpoolD., PreskittJ.T.The response of retroperitoneal fibrosis to tamoxifen. Surgery.1991; 109(4): 502–506.
18.
LoffeldRJLF, van WeelT.F.Tamoxifen for retroperitoneal fibrosis. [letter]. Lancet.1993; 341(8841): 382.
19.
BrooksA.P., ReznekR.H., WebbJ.A.W., BakerL.R.I.Computed tomography in the follow-up of retroperitoneal fibrosis. Clin Radiol.1987; 38(6): 597–601.
20.
BensonJ.R., BaumM.Tamoxifen for retroperitoneal fibrosis. [letter]. Lancet.1993; 341(8848): 836.
21.
BalducciC., LilliC., StabelliniG.. Human desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by Toremifene. BMC Cancer.2005; 5(1): 22.
22.
PemmarajuN., MunsellM.F., HortobagyiG.N., GiordanoS.H.Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol.2012; 23(6): 1471–1474.
23.
PrattD.S., KnoxT.A., ErbanJ.Tamoxifen-induced steatohepatitis. [letter]. Ann Intern Med.1995; 123(3): 236.
